Panbela Therapeutics Inc PBLA

Healthcare Biotechnology

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is involved in enrolling patients in its randomized double-blind placebo-controlled clinical trial for the treatment of pancreatic cancer. The Company's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X). Ivospemin is a polyamine analog designed to induce polyamine metabolic inhibition (PMI). Flynpovi is a combination of CPP-1X (eflornithine) and sulindac. It has a dual mechanism of action whereby it suppresses the synthesis of new polyamines and increases the export and catabolism of polyamines from the diet and microbiome. Eflornithine is being developed as a single-agent tablet or high-dose powder sachet for several indications, including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 diabetes metastatic castration-resistant prostate cancer, and STK-11 mutant NSCLC.

OTCQB:PBLA - Post by User

Panbela Therapeutics Inc > PBLA ..... Ho Hum....this could take all day ; )

<< Previous

Bullboard Posts

Next >>

Comment by Iseneschalon Jan 26, 2024 11:52am

35 Views

Post# 35847150

RE:PBLA ..... Ho Hum....this could take all day ; )

Well Folks....yes that includes all the SH audience ; .......

R u still watching???

It just broke out of the sideways channel pattern.... volume has only increased marginally.

I'm expecting a big push higher....eventually....might get some oscillations here...all those DT'ers flipping for peanuts

Go for the juggler folks...over $6

<< Previous

Bullboard Posts

Next >>

3 Mid-Sized Stocks to Consider This Season